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Discrete adipose-derived stem cell
subpopulations may display differential
functionality after in vitro expansion
despite convergence to a common
phenotype distribution
Frederik Mølgaard Nielsen1, Simone Elkjær Riis1, Jens Isak Andersen1, Raphaëlle Lesage2, Trine Fink1,
Cristian Pablo Pennisi1 and Vladimir Zachar1*
Abstract
Background: Complex immunophenotypic repertoires defining discrete adipose-derived stem cell (ASC) subpopulations
may hold a key toward identifying predictors of clinical utility. To this end, we sorted out of the freshly established ASCs
four subpopulations (SPs) according to a specific pattern of co-expression of six surface markers, the CD34, CD73, CD90,
CD105, CD146, and CD271, using polychromatic flow cytometry.
Method: Using flow cytometry-associated cell sorting and analysis, gating parameters were set to select for a CD73+CD90
+CD105+ phenotype plus one of the four following combinations, CD34−CD146−CD271− (SP1), CD34−CD146+CD271−
(SP2), CD34+CD146+CD271− (SP3), and CD34−CD146+CD271+ (SP4). The SPs were expanded 700- to 1000-fold, and their
surface repertoire, trilineage differentiation, and clonogenic potential, and the capacity to support wound healing were
assayed.
Results: Upon culturing, the co-expression of major epitopes, the CD73, CD90, and CD105 was maintained, while
regarding the minor markers, all SPs reverted to resemble the pre-sorted population with CD34−CD146−CD271− and
CD34−CD146+CD271− representing the most prevalent combinations, followed by less frequent CD34+CD146−CD271−
and CD34+CD146+CD271− variants. There was no difference in the efficiency of adipo-, osteo-, or chondrogenesis by
cytochemistry and real-time RT-PCR or the CFU capacity between the individual SPs, however, the SP2CD73+90+105+34-146+271-
outperformed others in terms of wound healing.
Conclusions: Our study shows that ASCs upon culturing inherently maintain a stable distribution of immunophenotype
variants, which may potentially disguise specific functional properties of particular downstream lines. Furthermore, the
outlined approach suggests a paradigm whereby discrete subpopulations could be identified to provide for a
therapeutically most relevant cell product.
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Background
Since the seminal discovery as cells being capable of tri-
lineage commitment [1], the adipose-derived stem cells
(ASCs) have come into the spotlight of cell-based and
regenerative approaches. There is ever-increasing num-
ber of clinical applications, but among the most signifi-
cant myocardial infarction [2], critical limb ischemia [3],
cytoprotection after radiation-induced tissue damage [4],
attenuation of acute kidney injury [5], and wound healing
[6] can be listed. From the point of regenerative effect,
however, it is not their differentiation potential, rather the
immunomodulatory, pro-angiogenic, and anti-apoptotic
properties [7–10] that play a role.
The immunophenotypical delineation of ASCs origin-
ally implicated expression of three hallmark epitopes,
the CD73, CD90, and CD105 [11–13]. They were found
expressed to a high degree, minimally around 60%, but
not completely [14–16], thus leaving open a question of
the significance of subpopulations with different surface
repertoire. In the face of wide acceptance of this basic
profile, attempts have been made to identify additional
markers that would be associated with ASC stemness.
Apart from the intracellular molecules, which are less
suitable for prospective analysis of live subpopulations,
such as Sox2 [17], Nanog [18], a whole array of surface
markers, including CD117 [19], CD24, CD34, CD146,
CD271 [20–23], CD133, CD200, CD362, Stro-1 [24],
and SSEA4 [25] have been reported. Out of these mole-
cules the CD34, CD146, and CD271 appeared to correl-
ate most consistently with physiological superiority or
higher plasticity [8, 11, 22, 23, 26–33]. The ASCs thus
represent a heterogenous mixture of stem and progeni-
tor cells, the composition and properties of which also
tends to change during in vitro growth. It is plausible
that some discrete subpopulations render specific thera-
peutic effect better than others. Hence, better under-
standing of the relationship between immunophenotype
and function would be instrumental in advancing the
clinical utility of ASCs.
Previous research highlighted the difficulty of inferring
the therapeutic potential for a specific application when
looking just at a few surface epitopes. As a result, a more
recent recommendation underscores examining directly
the functional properties using appropriate in vitro
surrogate testing for the particular in vivo effect, in order
for dedicated batches of ASCs to become a valid thera-
peutic product [34]. Since the establishment of surface
markers as clinical predictors would be highly beneficial,
we propose an approach whereby a fine delineation of
discrete subpopulations on the basis of more complex co-
expression repertoire of multiple markers would be under-
taken. To this end, we set out to investigate four of the
most prevalent subpopulations based on a polychromatic
staining protocol consisting of six selected markers,
including CD34, CD73, CDC90, CD105, CD146, and
CD271. The FACS purified cells were subsequently grown
and analyzed in cloning, differentiation, and wound-
healing assays.
Methods
ASC isolation and culture
The stromal vascular fraction (SVF) was prepared from
abdominal subcutaneous fat of a male donor (44 years,
BMI 25.4) according to a procedure described previously
by our laboratory [35]. Before donation, a written
informed consent was obtained, and the protocol was
approved by the regional committee on biomedical
research ethics of Northern Jutland, Denmark (project
no. VN 2005/54). This study complied with the princi-
ples of the Declaration of Helsinki.
The suspension was seeded sparsely and grown in α-
Minimum Essential Medium with GlutaMAX (A-MEM)
supplemented with 10% fetal calf serum (FCS) and anti-
biotics (all from Invitrogen, Taastrup, Denmark) for
5 days before sorting (P0). After the sorting, the cultures
were established at a density of 500 cells/cm2 and
allowed to reach a confluency of 80% (P1). At this point,
the cells were passaged using TrypLE (Invitrogen), and
reseeded at a density of 1000 cells/cm2 (P2). Cells were
grown under identical conditions during passage
three (P3). Specific investigations were performed at the
end of passages two and three as indicated in Fig. 1.
Flow cytometric analysis and cell sorting
The viability and six surface epitopes were analyzed sim-
ultaneously on the trypsinized cells using the Live/Dead
Fixable Aqua Dead Cell Stain Kit (Molecular Probes,
Taastrup, Denmark) and a batch of directly labeled anti-
bodies (all from BD Biosciences, Albertslund, Denmark),
respectively (Table 1). The cells were incubated first with
the viability reagent for 20 min, followed by a mixture of
antibodies optimally diluted in phosphate-buffered saline
with 0.1% BSA and 0.25 mM HEPES for 30 min. The
working dilutions were based on previous titrations. All
incubations and washings were done at 5 °C in the dark.
In addition to experiment samples, samples each missing
one of the antibodies were prepared to provide for
fluorescence minus one (FMO) controls.
A series of optimization steps was carried out prior to
analysis and sorting using the MOFLO Astrios EQ and
the Kaluza 1.3 software package (both Beckman Coulter,
Copenhagen, Denmark). The Sphero Ultra Rainbow
Single Peak Fluorescent Particles (Spherotech, Salt Lake
City, USA) were used for the optimization of stream align-
ment and quality control (QC). Furthermore, a battery of
beads was used to ensure that the flow cytometer was
fine-tuned to discriminate between noise and dimly
stained cells and that each channel was set within its
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linear range of signal amplification. This was especially
important, since the flow cytometer used represents a
stream-in-air design with manual calibration of the
stream. Consequently, the Sphero Ultra Rainbow Six Peak
Fluorescent Particles (Spherotech) were used to determine
signal-to-noise ratio (S/N), the linear range and the coeffi-
cient of variation (CV) at a range of voltage settings for
each of the photomultiplier tubes (PMTs) (Fig. 2a and b)
as described previously [36], thus providing basis for
optimization of PMT voltages for each of the specific
fluorochromes utilized in the present setup. The PMT
voltages were determined with the aid of the BD Comp-
Beads Anti-Mouse Ig, κ (BD Biosciences) conjugated to
our antibody arsenal. The settings providing the highest
S/N ratio without the occurrence of double negativity
were used (Fig. 2c) and the gains were adjusted so an
unstained sample produced a bell-shaped emission with a
median fluorescence of 101. Great care was also taken to
ensure reproducibility between the experiments. To
achieve this, the Sphero Ultra Rainbow Single Peak
Fluorescent Particles were run along each sample to con-
firm the uniformity of the CV and the geometric mean of
the fluorescence intensity (GMFI) (Fig. 2d). Acceptable
flow cytometer alignment was defined as a successful
automatic quality control combined with the CVs and
GMFIs varying less than 4.5% and PMT voltages being
within the linear range. Finally, compensation values were
established for each run to control for the bleed-through
utilizing the BD CompBeads Set Anti-Mouse Ig, κ and the
AutoComp Wizard in Summit 6.1 (Beckman Coulter) and
the Kaluza 1.3 when analyzing data. Additional manual
fine-tuning of the compensation matrix was done when-
ever necessary.
To validate the cells for analysis and sorting, four gates to
exclude flow cytometer instability (Fig. 2e), noise and cell
debris (Fig. 2f), cell doublets (Fig. 2g), and dead cells
(Fig. 2h) were invoked. Based on this strategy, the cutoff
value for the positivity was defined as the top 2.5 percentile
Fig. 1 Scheme of the experimental setup. SVF harvested from a single donor was initially seeded out and cultured until reaching confluency (P0).
The ASCs were at this point sorted out into a control group (CFCS) or four subpopulations (SP1–4) based on a forward- vs. side-scatter (FSC/SSC)
gate or patterns of CD markers co-expression, respectively. All sorted populations were subsequently analyzed for immunophenotype at passages
P0, P2, and P3, and adipo-, osteo-, and chondrogenic differentiation, clonogenic potential, and wound healing capacity at passage P2. The entire
experiment was performed twice independently. Abbreviations: SVF stromal vascular fraction, C control, SP subpopulation, FSC forward scatter, CFU
colony-forming unit
Table 1 Reagents used for flow cytometric analysis and sorting
Reagent Fluorochrome Ex-Em (nm)
Live/Dead Aqua Blue 355-530/11
anti-CD34 BUV395 355-395/25
anti-CD73 FITC 488-513/26
anti-CD90 PerCP-Cy5.5 488-710/45
anti-CD105 APC 640-664/22
anti-CD146 PE-CF594 561-614/20
anti-CD271 PE-Cy7 561-795/70
Ex excitation wavelength, Em emission window
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Fig. 2 (See legend on next page.)
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of the FMO control for a given marker. Added measures
were taken to preserve the viability and yield of the cells
from the sorting procedure. To this end, the flow-line was
cleaned by using the Moflo FACS Cleaner (Beckman
Coulter) and 70% ethanol, and the collecting tube holder
was cooled to 5 °C. Moreover, the dissociation of cells was
aided with the Accumax Solution (Sigma-Aldrich, Brøndby,
Denmark) and straining through a 35-μm cell strainer (BD
Biosciences). The sorting was performed with the sample
chamber and the sheath fluid tank pressures being 25.3 and
25 psi, respectively, and the voltage at the deflection plates
was set at 3800 V. Stable deflection beams were optimized
through careful setting of charge phase and defanning. The
cells were sorted in a sterile sheath fluid into the growth
medium containing 20% FCS and 0.25 mM HEPES.
CFU assay
The frequency of colony-forming units (CFUs) was
determined directly in the sorted populations and in the
populations after each of the ensuing passages by limit-
ing dilution [37]. In brief, the cells were seeded in
quadruplicates in densities ranging from 1 to 30 cells
per well, and after 14 days, the cultures were fixed with
4% formaldehyde (AppliChem, Esbjerg, Denmark) and
stained using 0.05% crystal violet (Sigma-Aldrich). Wells
containing one or more colonies were noted and the
proportion of CFUs calculated using L-Calc Software
(Stem Cell Technologies, Vancouver, Canada). Data not
following the Poisson distribution were excluded from
analysis.
Endothelial scratch assay
Human dermal microvascular endothelial cells (Promo-
Cell, Heidelberg, Germany) were seeded in quadruplicates
in a 96-well plate at 12,000 cells/cm2 in Endothelial Cell
Growth Medium MV2 (MV2; PromoCell). After reaching
confluency, the monolayers were scratched using the
Wounding Pin Tool (V&P Scientific, Radway Green,
United Kingdom), and the MV2 media was added as nega-
tive control, α-MEM supplemented with 10% FCS and an-
tibiotics was added as vehicle control, and the conditioned
media from P2 ASCs (CFSC) or sorted subpopulations
(SP1–4) were added for testing the wound-healing
properties. The conditioned media were based on α-MEM
supplemented with 10% FCS and antibiotics and produced
during a 3-day culture period prior to the end of P2. All
FCS used in this study originated from the same batch
and lot. The progress of damage reparation was moni-
tored by time-lapse microscopy every 2 hours for a total
of 12 hours using a Zeiss Axio Observer.Z1 microscope
equipped with an AxioCam MRm camera and AxioVision
software package (Carl Zeiss, Birkerød, Denmark). Relative
wound size at each time point was analyzed using the
TScratch software [38].
Differentiation assays
ASCs were analyzed for their multilineage capacity by
differentiating toward adipo-, osteo- and chondrogenic
lineages using procedures as implemented in our labora-
tory [39–43]. The adipogenic differentiation was initi-
ated in A-MEM with 10% FCS, 0.1 μM dexamethasone,
0.45 mM 3-Isobutyl-1-methylxanthine (IBMX), 0.17 μM
insulin, and 0.2 mM indomethacin (all from Sigma-
Aldrich). Lipid accumulation was visualized by staining
with oil red O (Sigma-Aldrich). For osteogenic induc-
tion, the cells were grown in A-MEM supplemented with
10% FCS, 0.1 μM dexamethasone, 50 μM L-ascorbic acid,
0.05 μM calcitriciol, and 10 mM glycerol-2-phosphate (all
from Sigma-Aldrich). Alizarin red (Sigma-Aldrich) was
used to reveal the mineralization of extracellular matrix.
The chondrogenesis was accomplished using micro-
mass cultures maintained in Dulbecco’s Modified
Eagle’s Medium supplemented with 25 mM glucose
(Invitrogen), 0.4 nM TGF-β1 (Sigma-Aldrich), 100-fold
diluted ITS-G (Gibco, Taastrup, Denmark), 0.35 μM L-
proline, 0.17 μM L-ascorbic acid 2-phosphate, and
0.1 μM dexamethasone (all from Sigma-Aldrich). The
extent of differentiation was assessed from thin paraffin
sections after staining with alcian blue 8GX (Sigma-
Aldrich).
Real-time RT-PCR
The transcriptional activation of lineage-specific differ-
entiation genes, including PPAR-γ2, Sox9, and Osteocal-
cin, and the reference genes, including cyclophilin A
(PPIA) and tyrosine 3/tryptophan 5-monooxygenase
(See figure on previous page.)
Fig. 2 Flow cytometric and gating strategy using the Ex640 - Em664/22 nm channel. a Spherotech 6 peak Rainbow beads were used to identify a
useful range of PMT potential. The bracket indicates voltage investigated during ensuing optimization. b PMT linearity and CV from the same
experiment. c The narrowed range of PMT voltages was analyzed for optimal S/N using BD Biosciences Compensation beads conjugated with the
labeled antibodies used in this study. The voltage that produced the highest S/N with no apparent double negativity was then chosen for each
channel and its respective antibody (in box). *Double negativity. d To ensure the reproducibility of the experimental setup, the Spherotech single
peak Rainbow beads were analyzed for 5000 events in each channel every time an experiment was conducted. e For sorting, the cells were first
gated using SSCHeight vs. time plot to control for the stability of the flow cytometer. f The noise and debris were removed using FSCHeight vs.
SSCHeight contour plot. g The doublets were discriminated and removed using FSCWidth vs. FSCHeight contour plot. h The live cells were identified
by means of a viability stain. Abbreviations: PMT photomultiplier, CV coefficient of variation, S/N signal-to-noise ratio, AGM average geometric
mean, GMFI geometric mean of fluorescence intensity, SSC side scatter, FSC forward scatter
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activation protein (YWHAZ), was carried out as de-
scribed previously [16, 44]. Briefly, total RNA was iso-
lated using the Aurum Total RNA Mini Kit (Bio-Rad,
Copenhagen, Denmark) and the purity and concentra-
tion were determined spectrophotometrically using the
Agilent RNA 6000 Nano kit (Agilent Technologies, Wald-
bronn, Germany). The iScript cDNA synthesis kit (Bio-
Rad) was used to carry out reverse transcription. The amp-
lification reactions were performed on a CFX Connect
Real-Time PCR Detection System (Bio-Rad) in a final vol-
ume of 20 μl containing 5 pmol of each primer (DNA
Technology, (Aarhus, Denmark) (Additional file 1: Table
S1) and 10 μl cDNA using SYBR Green PCR Supermix
(Bio-Rad). The thermal cycling protocol involved ini-
tial denaturation at 95 °C for 3 min and was followed
by 40 cycles of denaturation at 95 °C for 10 sec and
primer annealing and elongation for 30 sec at prede-
termined optimal primer-specific temperatures. To
test for the specificity of the product, a melt curve
function of the CFX Manager software (Bio-Rad) was
invoked. A standard curve derived from the pool of
all cDNA samples was used to calculate relative ex-
pression of each gene.
Statistical analysis
The data were derived from two identical, independent
experiments each with replicates, and technical repli-
cates, whenever applicable, and they are presented as
mean + standard error of the mean (SEM). Prior to stat-
istical analysis using one-way ANOVA, the normality of
distribution and equality variances were tested with the
Shapiro-Wilk and Equal Variance Tests in SigmaPlot
12.0, respectively (Systat Software, San Jose, CA, USA).
Statistical significance was assigned to p values < 0.05.
Results
Evolution of the subpopulation phenotype
The cells expanded during P0 were sorted into four sub-
populations (SP1–4) based on the co-expression of three
major epitopes CD73, CD90, and CD105, and four dif-
ferent combinations of minor markers, including CD34
−CD146−CD271−, CD34−CD146+CD271−, CD34+ CD146
+CD271−, and CD34−CD146+CD271+ (Fig. 3). Addition-
ally, a population was included (CFSC), which was sorted
on a simple FSC/SSC gate in order to control for the po-
tential impact the sorting procedure might introduce
into the experiment.
The expression patterns were investigated at the time
of sorting (P0) and for the subpopulations at passages P2
and P3 (Fig. 1). With respect to major markers, all of the
cells at P0 expressed CD90 and CD105, in contrast to
CD73, which was expressed on 96.3% of cells. As a gen-
eral paradigm regarding the CD73 and CD90, the level
of expression increased in the course of culturing, as
indicated by an increase in the GMFI. Thus, the CD73
featured a 1.5-fold upregulation at P3 relative to the ini-
tial phenotype, while the CD90 was upregulated 1.7
times. At P3 cells in all subpopulations co-expressed the
three major markers. As for the minor markers, most of
the cells at P0 were negative for CD34 and CD271, leav-
ing thus 24.3% and 3.8% of cells positive, respectively,
while a majority of the cells were positive for the CD146
(31.5%). It is interesting that upon culturing, the expres-
sion pattern of all minor epitopes became highly remin-
iscent of that of the CFSC, irrespective of whether the
epitope was selected in a given subpopulation or not.
This evolution, however, occurred more rapidly for
CD146 and CD271, where it appeared already at P2,
whereas, for CD34 it was delayed until P3.
When considering the surface repertoire at P0, it is
significant that four distinct combinations of markers
constituted more than 90% of the whole population
(Fig. 4). The largest subpopulation (54.1%) featured only
the major epitopes, whereas the three smaller subpopu-
lations co-expressed in addition single markers CD34
(15.7%) or CD146 (15.3%), or combination thereof
(6.7%). In the current investigation, we opted to follow a
minor subpopulation co-expressing the CD146 and
CD271 (1.1%) rather than the more abundant CD34+
subpopulation based both on the literature and our own
data [45, 46]. Upon in vitro expansion, the repertoire
within the CFSC cultures (CFCS at P2) redistributed and
stabilized in a manner that the cells co-expressing exclu-
sively the major markers remained a dominant although
slightly smaller subpopulation (47.5%), the CD146+ sub-
population became the second most abundant (35.3%),
the subpopulations expressing CD34 alone or in com-
bination with CD146 decreased to 11.1% and 2.9%,
respectively, and the CD146 and CD271 double-positive
cells remained to represent only a small proportion of
1.7%. Interestingly, all sorted subpopulations re-expressed
the missing epitopes so as to assume the generic paradigm
of CFSC cells, irrespective of the duration of culture.
Slightly differently behaved the cells sorted for the expres-
sion of CD146 (SP2), where this phenotype remained the
most prevalent one throughout the culturing (P2, 56.6%;
P3, 46.0%).
Subpopulation stem cell characteristics
The trilineage differentiation potential of the CFSC and
SP1–4 cells was tested at P2 by subjecting the cultures
to adipo-, osteo-, and chondrogenic regimens (Fig. 5).
The qualitative assessment by bright-field microscopy
demonstrated a comparable extent of differentiation ir-
respective of the phenotype (Fig. 5a). This was further
corroborated by real-time RT-PCR, where no significant
difference in the expression of major differentiation
markers could be found among the discrete
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subpopulations (Fig. 5b). The similarity between the sub-
populations was at the same stage of culture also con-
firmed by the CFU analysis, which could not reveal any
significant differences in the efficiency of maintenance of
the precursor cells (Fig. 5c).
Subpopulation wound-healing capacity
The capacity of the CFSC and SP1–4 cells to promote
wound healing was examined at P2 using a scratch assay
(Fig. 6 and Additional file 2: Figure S1). The phase-
contrast microscopy indicated a differential rate of wound
closure upon stimulation with the ASC conditioned
media, with SP2 supernatant being apparently the most
efficient (Fig. 6a). The kinetic analysis of the monolayer
response to different media demonstrated the superiority
of SP2 throughout the assay period, and a statistically sig-
nificant effect could be confirmed after 12 hours (Fig. 6b).
Discussion
The ASCs as well as other mesenchymal stem cells
derived from numerous tissue types were shown to
express in vivo and in vitro a gamut of surface markers,
the specific combinations of which may ultimately define
distinct repertoires [26, 31, 33, 46–50]. Previous studies
suggested that some of the markers may play a role in
the ASC functionality, such as angiogenesis, differenti-
ation, migration, and secretome [1, 27, 50–52]. These
approaches were based on the selection of single surface
markers and characterization directly after sorting,
giving thus a limited emphasis to the co-expression
patterns [29, 31, 45, 48, 53–55]. In continuation of these
efforts we sought to obtain insight into how more com-
plex surface marker variants are maintained during
culturing and whether they have a potential to provide
for progeny populations with enhanced specific func-
tionality. Such study would further our understanding of
the significance of different combinations of more and
less frequent markers that specify the discrete subpopu-
lations. It is plausible that overrepresentation of unique
repertoires in certain donors would provide at least
partial explanation for great inter-individual differences
in particular regenerative applications. Consequently,
Fig. 3 Evolution of immunophenotype after sorting according to specific co-expression patterns. The subpopulations with different combinations
of six CD markers (SP1–4) and the control population sorted on the forward scatter (CFSC) were cultured and analyzed at the end of the next two
passages (P2 and P3). The expression levels are plotted against the 488-SSC as contour plots to visualize progression in expression patterns. P0
represents analysis of the cell suspension just prior to sorting, and the red lines represent cutoff values for sorting gates as determined from FMOs.
Abbreviations: FMO fluorescence minus one
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Fig. 4 Frequency of repertoires based on co-expression of six selected CD markers as a function of in vitro expansion. Sorted subpopulations SP1–4 and
the control population CFSC sorted on the forward scatter were analyzed at the end of passages two and three (P2, P3). All possible repertoires are shown
at P0. Only co-expression variants for CD34, CD146, and CD271 are shown at P2 and P3, since the CD73, CD90, and CD105 markers were
invariably co-expressed. The shaded area at P0 at sorting denotes profiles associated with ASC hallmark markers, and the frequencies are
also highlighted with individual bars. The legend indicates full profiles of the originally sorted repertoires, and these are highlighted in
the plots by a stippled line. The data are presented as means from two independent experiments. ■ The marker is expressed. □ The
marker is not expressed. Abbreviations: N.A. not applicable
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specific donors or subpopulations could be rationally
selected to provide for optimal clinical response.
Based on previous investigations [14, 15, 20–23], we
identified CD73, CD90, CD105, CD34, CD146, and
CD271 as six surface markers with major relevance
for determination of ASCs. In this study, not all com-
binations appear equally permissible, but 95% of early
ASCs (P0) are found in the compartment defined by
CD73+90+105+ phenotype. Of these cells, 54% does
not express any of the other studied markers, 16%
co-express CD34, 15% co-express CD146, and 7% co-
express both of them. To study the effect of in vitro
culture on the properties of discrete subpopulations,
we opted to include a minor SP4CD146+271+ in favor
of the sole CD34+ variant since our previous investi-
gation indicated frequent occurrence of this pheno-
type, ranging from 5 to 20% [46]. Low frequency of the
minor combination CD146+CD271+ in the current
study underscores significance of factors underlying
interindividual variability, in this case most likely those
related to age [47].
Interestingly, our findings show that in the progeny
population stemming from the single sorted profile, a
distribution of phenotypic variants reappears so as to
resemble to original pre-sorted population (P0). Depend-
ing on the originally selected markers, all downstream
lines thus as a result of culturing gained, lost, or gained
and lost one or more markers, ultimately resembling
each other. This indicates that a restricted heterogeneity
rendered by distinct physiologically important reper-
toires is critical for stability and viability of ASC
cultures, and further raises the question about possible
mechanisms involved in the mutual intervariant stimula-
tory interactions enabling survival in vitro. Importantly,
despite obvious resemblance, the downstream lines may
display differential functionality under appropriate con-
ditions. Selection for the CD73+CD90+CD105+CD34
−146+271− phenotype (SP2) clearly resulted in a line with
A
B
Fig. 5 Stem cell properties of the phenotypically selected subpopulations SP1–4 and the control subpopulation CFSC sorted on the forward scatter. a
Histochemical analysis of the trilineage differentiation using oil red O, alizarin red, and alcian blue for adipo-, osteo-, and chondrogenesis, respectively.
The insets depict fourfold zoom from the large field micrographs. The scale bar denotes 100 μm. b Transcriptional expression of differentiation
regulators by real-time RT-PCR from two independent experiments carried out in triplicate (n = 6). c The colony-forming capacity was assessed after
staining with crystal violet from two independent experiments carried out in replicate (n = 16). The data are presented as mean + SEM
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increased endothelial stimulation. Given the scope of
epitopes selected in this study, it seems that of the minor
markers, the CD146 is necessary and sufficient to pro-
vide for augmented paracrine support of endothelial
cells. An explanation for this functional significance of
the CD146 probably stems from the fact that it has been
identified as a cell adhesion molecule and a hallmark
epitope of endothelium regulators, the pericytes. Peri-
cytes are perivascular cells that have been located peri-
vascularly in almost all tissues [29], and in addition to a
major role in angiogenesis through an interplay with
endothelial cells [21, 28, 56–58], they have been found
to influence homeostasis through contraction of blood
vessels [21], or regulate coagulation and lymphocyte
activation and migration [59]. Nevertheless, to confirm
the existence of true pericyte phenotype, the presence of
additional markers, such as the α-SMA, NG2, and
PDGF-B receptor and absence of CD31, CD34, CD45,
and CD56 would have to be confirmed [21, 27–30, 57].
There is no obvious explanation why selection of SP2
repertoire would produce such functional outcome when
all other progeny lines also contained this variant in a
substantial proportion. The level of CD146 expression
could be of importance, as was suggested previously by
some investigators [31, 33], but that such simple quanti-
tative indicator plays a role does not seem to be sup-
ported by our data. The answer thus may reside in
differences between relative proportions of individual
repertoires within the progeny lines or in the way how
CD146 expressed in the context of other epitopes de-
fines the selected parental population. The issue of more
defined subpopulations appears intricate, since some
previous data contradict our findings by highlighting the
CD34+CD146+ phenotype as highly pro-angiogenic [45].
Clearly, further studies are necessary to shed more light
on the biological significance of complex repertoires,
especially in terms of molecular events involved in the
secretion of paracrine factors. By the same token, it
would be of interest to determine how significant is the
association of CD146 with the regenerative potential in the
clinical setting. Since, as mentioned above, this phenotype
plays a role in revascularization processes, it can be envis-
aged that in conjunction with appropriate preconditioning
regimen, such as hypoxia [8, 15, 16, 60–63], substantially
improved therapeutic outcome would be achieved.
A
B
Fig. 6 Modulation of endothelial wound healing by conditioned
media derived from the phenotypically selected subpopulations SP1–4
and the control subpopulation CFSC sorted on the forward scatter. a
Representative micrographs from the scratch assay. Cell-free surface is
demarcated by a red line. The scale bar denotes 200 μm. b Quantitative
assessment of the wound healing from two independent experiments
carried out in replicate (n = 12). The data are presented as mean + SEM.
*Statistically different from CFSC and all other SPs at p < 0.05
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Conclusions
Downstream lines from ASCs selected on the basis of
specific surface repertoires have a tendency to assume
upon culturing a phenotypical distribution reminiscent
of the original population. Depending on the originally
selected markers, all lines thus as a result of culturing
gained, lost, or gained and lost one or more markers,
ultimately resembling each other. Although general as-
says for stemness, such as the trilineage differentiation
and CFU capacity, could not reveal any difference be-
tween the lines, specific functional analysis based on
the endothelial model of wound healing demonstrated
superiority of one of the propagated subpopulations.
This property appeared to be rendered by selecting for
the CD73+CD90+CD105+CD34−CD146+CD271− pheno-
type. The sole expression of CD146 on the background
of the CD73, CD90, and CD105 seems to be critical,
since co-expression of additional minor marker, such as
CD34 or CD271 abrogated the functional advantage.
Based on this example, it is possible that other discrete
subpopulations may provide for progeny populations that
would have the potential to deliver in a specific clinical
scenario an effect superior to that of crude ASCs.
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